A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.
- 12 Aug 2015 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 22 Jul 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016, according to ClinicalTrials.gov record.